Skip to content

Kynam Capital Management, LP 13F Holdings · Q2 2026

Kynam Capital Management, LP reported 32 securities worth $1.81B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: CLDX (10.95%), SNDX (9.73%), PCVX (9.39%). Among its top 25 positions this quarter: 2 new, 10 added, 6 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1CLDXCELLDEX THERAPEUTICS INC NEW$198.1M10.95%5.3MTrimmed
2SNDXSYNDAX PHARMACEUTICALS INC$176.0M9.73%8.1MHold
3PCVXVAXCYTE INC$169.9M9.39%2.9MHold
4COGTCOGENT BIOSCIENCES INC$141.9M7.84%3.7MTrimmed
5VERAVERA THERAPEUTICS INC$124.0M6.85%2.9MTrimmed
6VRDNVIRIDIAN THERAPEUTICS INC$118.6M6.55%6.5MAdded
7TVTXTRAVERE THERAPEUTICS INC$113.6M6.28%2.0MTrimmed
8BEAMBEAM THERAPEUTICS INC$97.5M5.39%2.8MTrimmed
9URGNUROGEN PHARMA LTD$89.6M4.95%2.4MAdded
10LEGNLEGEND BIOTECH CORP$86.7M4.79%3.0MAdded
11CTMXCYTOMX THERAPEUTICS INC.$81.4M4.50%21.7MAdded
12RLAYRELAY THERAPEUTICS INC$61.7M3.41%3.3MAdded
13CGEMCULLINAN THERAPEUTICS INC$56.7M3.13%3.1MHold
14MBXMBX BIOSCIENCES INC$51.6M2.85%934,799Hold
15IMCRIMMUNOCORE HLDGS PLC$43.7M2.41%1.4MAdded
16NRIXNURIX THERAPEUTICS INC$29.0M1.60%1.2MHold
17STROSUTRO BIOPHARMA INC$29.0M1.60%872,558Hold
18BCRXBIOCRYST PHARMACEUTICALS INC$25.2M1.39%2.5MTrimmed
19PHVSPHARVARIS N V$22.9M1.26%661,795Added
20SMMTSUMMIT THERAPEUTICS INC$17.5M0.97%1.2MNew
21PRLDPRELUDE THERAPEUTICS INC$12.9M0.71%2.4MAdded
22INSMINSMED INC$10.7M0.59%100,000New
23BNRBURNING ROCK BIOTECH LTD$10.5M0.58%1.2MAdded
24GERNGERON CORP$8.8M0.48%6.8MHold
25AMRNAMARIN CORP PLC$8.5M0.47%532,982Added

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR